망막 하 공간에 액세스하기위한 대안의 검증 사출 방법를 통해를 Transcleral 후방 접근

Executive Industry Relevance

This transcleral posterior subretinal injection method addresses a key challenge in preclinical ophthalmology: delivering therapeutic agents to the subretinal space while minimizing surgical trauma and preserving retinal integrity. By avoiding retinal penetration and vitreous disruption, the technique enables more accurate assessment of drug efficacy in rodent models of retinal degeneration. This supports de-risking of target validation and lead identification efforts in vision science pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables precise delivery of viral vectors, pharmacological agents, or stem cells to the subretinal space for functional target validation in retinal disease models.
• Operational Value: Minimizes confounding tissue damage, allowing clearer interpretation of therapeutic effects on photoreceptors and RPE.

Screening & Assay Development

• Scientific Value: Produces consistent, reproducible subretinal delivery with quantifiable outcomes via OCT and fundus imaging.
• Operational Value: Standardizes injection depth and location (0.5 mm from optic nerve), reducing variability across experiments and operators.

Translational & Preclinical Research

• Scientific Value: Supports longitudinal assessment of retinal structure and function due to rapid retinal reattachment and minimal chronic scarring.
• Operational Value: Compatible with postoperative monitoring using OCT, fundus imaging, and ERG to evaluate therapeutic durability.

Pipeline & Workflow Integration

The method fits within the discovery-to-preclinical continuum by enabling reliable delivery of candidate therapeutics to the subretinal space, a critical step before efficacy testing in degenerative retinal models.

• Discovery Biology: Facilitates hypothesis testing by allowing targeted delivery of agents to interrogate retinal pathways and cell-specific functions.
• Screening: Enables standardized preparation of disease models for compound screening with minimal procedural failure.
• Analytics: Generates clear OCT- and fundus-based readouts to quantify retinal detachment resolution and functional recovery over time.
• Translational Research: Supports continuity from discovery to preclinical validation by preserving retinal architecture for accurate biomarker and functional assessments.
• Enterprise Reuse: Reusable across studies involving viral vectors, proteins, or cell-based therapies for retinal degeneration.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by reducing surgical artifacts that could mask or mimic therapeutic effects.
• Operational Value: Short procedure time (10–15 minutes per eye) and low failure rate improve throughput in preclinical studies.
• Strategic Value: Reduces biological noise in efficacy data, supporting better go/no-go decisions in target prioritization.
• Portfolio Impact: Enables risk-adjusted advancement of retinal therapeutics by providing cleaner preclinical data on mechanism and durability.

Implementation Considerations

• Requires microsurgical expertise and fine motor control for sclerotomy and needle placement.
• Dependent on specialized instrumentation including Vannas scissors, 22.5° ophthalmic blade, and 33-gauge beveled needle.
• Necessitates standardized postoperative care including antibiotics, analgesics, and monitoring for retinal reattachment.
• Adaptation to other model systems may require adjustment of incision size and needle angle based on ocular anatomy.
• Limited to posterior segment access; not suitable for anterior segment or intravitreal delivery applications.

Biopharma FAQs